Plus, drug manufacturing in space.
 

The Beacon

The Beacon

By Kate Turton

Hello Beacon readers! 

The Camberwell beauty might have a lovely name and an even prettier appearance, but it and other butterflies may have developed their patterns for a more prosaic reason: Bold markings and beating wings create so-called "motion dazzle", an optical illusion that confuses its predators.

Researchers studying this natural defense combined high-speed filming of real butterflies and computer modelling, along with recruiting 100 human volunteers to carry out 3,000 virtual butterfly-catching experiments.

They watched videos and tried to catch butterflies by tapping a screen. The butterflies that had been predicted to produce stronger visual confusion seemed to succeed, causing participants to aim farther ⁠behind them.

What local or global good news have you read this week that you would like to share? Email me at beacon@thomsonreuters.com and I might share it in a future edition.

 

A Camberwell beauty butterfly in Le Planay, Areches-Beaufort, France. Emmanuelle Briolat/Handout via REUTERS

In their own words

Jolyon Troscianko, a professor at the University of Exeter, said: "Predation experiments with live birds and butterflies would have been ideal in many ways, but likely impossible and unethical in practice."

 

Cliff Diving World Series champs crowned in Italy

Play 

The 2026 Cliff Diving World Series came down to the fifth and final stop in Polignano a Mare, Italy with Australia’s Rhiannan Iffland and Brit Aidan Heslop claiming the overall win for the season despite not reaching the podium at the finale. 

 

In other good news

  • Kashmir's 600-year-old wedding-feast tradition adapts to modern times
  • Maxhosa Africa brings pan-Africanism to Paris Fashion Week
  • Swiss archaeologists redraw Roman maps after drought discoveries
  • Japan's 11-year-old esports prodigy wins Asiad gold and rival's praise
  • Taylor Swift makes VMAs history and dedicates award to Dolly Parton
  • Giant pandas arrive at Zoo Atlanta for 10-year stay
  • China's first Tibetan UFC fighter chases title dream and inspires fans
  • California governor signs PFAS pesticide tracking bill
 

Varda fundraises to scale orbital drug manufacturing

Delian Asparouhov, co-founder of Varda Space Industries, in New York City. REUTERS/Brendan McDermid/File Photo

Drugs in space? It's not quite what you think. In-space manufacturing startup Varda Space told Reuters it has raised $250 million in a Series D round at a $1.6 billion valuation, part of its mission to produce pharmaceuticals in microgravity. 

There are certain products whose development in space yields better efficiencies or purities than in the gravity of Earth.

Varda has already deployed six missions to orbit. These were undertaken with its free-flying W-Series capsule. It plans to debut a next-generation capsule in 2030.

 

Sponsors are not involved in the creation of newsletters or other Reuters news content. Advertise in this newsletter or on Reuters' website